Comparative Pharmacology
Head-to-head clinical analysis: DEXILANT versus PANTOPRAZOLE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXILANT versus PANTOPRAZOLE SODIUM.
DEXILANT vs PANTOPRAZOLE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexlansoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Proton pump inhibitor. Suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
30 mg orally once daily for up to 8 weeks; for healing esophagitis, 60 mg orally once daily for up to 8 weeks; maintenance 30 mg orally once daily.
40 mg orally once daily for 8 weeks for erosive esophagitis; 40 mg intravenously once daily for 7-10 days for GERD with esophagitis.
None Documented
None Documented
Terminal elimination half-life is 1–2 hours in healthy subjects, but due to prolonged gastric acid suppression via irreversible binding to proton pumps, duration of action exceeds 24 hours. Half-life is not directly correlated with pharmacodynamic effect.
Terminal elimination half-life: ~1 hour (range 0.5–2 h); clinically, acid suppression lasts longer due to covalent binding to proton pumps
Renal (approximately 50% as inactive metabolites) and fecal (approximately 50% as inactive metabolites).
Renal: ~71% as metabolites; fecal: ~18% via bile; unchanged renal excretion: <1%
Category C
Category A/B
Proton Pump Inhibitor
Proton Pump Inhibitor